What is Entasis Therapeutics Holdings Inc. (ETTX)?

Entasis Therapeutics Holdings Inc. (ETTX) is a stock in the Healthcare sector, Biotechnology industry. View full analysis on Stocks360.

What is the current price of ETTX?

The current price of ETTX is $2.19. Prices are updated in real time on Stocks360.

What is ETTX's price-to-earnings (PE) ratio?

ETTX's trailing twelve-month PE ratio is -2.19, based on current price and earnings per share data available on Stocks360.

Entasis Therapeutics Holdings Inc. (ETTX)

Stock analysis · NASDAQ · Healthcare · Biotechnology

$2.19

Market Cap

N/A

PE (TTM)

-2.19

EPS (TTM)

N/A

Dividend Yield

0.00%

Beta

1.33

Day Range

$2.19 – $2.20

52-wk Range

$0.00 – $0.00

Avg Volume

N/A

Volume

0.00

Entasis Therapeutics Holdings Inc. (ETTX) is a publicly traded company in the Healthcare sector. Latest price: $2.19. Trailing PE -2.19. Sign in to Stocks360 for full DCF valuation, fundamentals, technicals, and AI-driven analysis.

Get full analysis → Short-Term Analysis →

You have viewed 5 SEO analysis pages

Unlock saved watchlists, personalized setups, and referral credits with a free Stocks360 account.

Continue with free signup

Earnings

Most Recent

Apr 27, 2022

EPS $-0.32 vs est. $-0.26

Missed by $0.06

Proprietary Signals

Signal snapshot temporarily unavailable.

About Entasis Therapeutics Holdings Inc.

Entasis Therapeutics Holdings Inc. operates as a clinical-stage biopharmaceutical enterprise, dedicated to the discovery, development, and market introduction of novel antibacterial solutions. Their core mission in the United States is to address severe infections stemming from pathogens that exhibit multidrug resistance. A flagship program in their pipeline is sulbactam-durlobactam (SUL-DUR), an innovative intravenous antibiotic. This promising candidate is currently undergoing Phase III clinical evaluation for its effectiveness in treating pneumonia and bloodstream infections caused by carbapenem-resistant Acinetobacter baumannii. The company's developmental efforts extend to several other therapeutic agents. Zoliflodacin, a distinct orally administered molecule, is also progressing through Phase III clinical trials, aimed at uncomplicated gonorrhea. Furthermore, ETX0282CPDP, an oral drug, is being assessed in Phase I studies for its potential in treating urinary tract infections. From their NBP platform, ETX0462 is another drug candidate, presently in the pre-clinical stage, targeting a range of multidrug-resistant gram-negative infections. Entasis maintains key partnerships to…

Valuation

Trailing twelve months. Multiples relative to current market price.
P/E (TTM)	-2.19×
P/S (TTM)	0.00×
P/B	3.32×
PEG	0.06×
P/FCF (TTM)	0.00×
EV / EBITDA	0.69×
EV / Sales	0.00×
Earnings Yield	-45.50%
Free Cash Flow Yield	0.00%

Fundamentals

Trailing twelve months. Source: financial statements via market data.
Enterprise Value	-$32.31M
Net Income (TTM)	$0.00
Free Cash Flow (TTM)	-$43.04M
Net Debt	-$32.31M
Working Capital	$30.11M
Gross Margin	0.00%
Operating Margin	0.00%
Net Margin	0.00%
Return on Equity	-112.91%
Return on Invested Capital	-151.03%